Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

Core Insights - Syndax Pharmaceuticals' Revuforj® (revumenib) was awarded Best New Drug at the Scrip Awards 2025, highlighting its significance in pharmaceutical development [1][3] - Revuforj is a first-in-class menin inhibitor, recently approved by the FDA for treating relapsed or refractory acute leukemia with specific genetic mutations [2][4] Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, including Revuforj and Niktimvo™ [22] - The company is committed to advancing cancer care through its pipeline and ongoing clinical trials [22] Product Details - Revuforj is FDA approved for treating relapsed or refractory acute leukemia with KMT2A translocation and acute myeloid leukemia with NPM1 mutation in patients aged one year and older [2][4] - The drug has received Orphan Drug Designation and Fast Track designation from the FDA, indicating its potential in treating serious conditions [6] Clinical Trials and Future Prospects - Multiple clinical trials for Revuforj are ongoing or planned, including studies in combination with standard therapies for newly diagnosed patients [5] - The company aims to unlock the full potential of its pipeline through continued research and development efforts [22]